|
1
|
Marraffini LA: CRISPR-Cas immunity in
prokaryotes. Nature. 526:55–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allemailem KS, Alsahli MA, Almatroudi A,
Alrumaihi F, Alkhaleefah FK, Rahmani AH and Khan AA: Current
updates of CRISPR/Cas9-mediated genome editing and targeting within
tumor cells: An innovative strategy of cancer management. Cancer
Commun (Lond). 42:1257–1287. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Piergentili R, Del Rio A, Signore F, Umani
Ronchi F, Marinelli E and Zaami S: CRISPR-Cas and its wide-ranging
applications: From human genome editing to environmental
implications, technical limitations, hazards and bioethical issues.
Cells. 10:9692021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allemailem KS, Almatroudi A, Rahmani AH,
Alrumaihi F, Alradhi AE, Alsubaiyel AM, Algahtani M, Almousa RM,
Mahzari A, Sindi AAA, et al: Recent updates of the CRISPR/ Cas9
genome editing system: Novel approaches to regulate its
spatiotemporal control by genetic and physicochemical strategies.
Int J Nanomedicine. 31:5335–5363. 2024. View Article : Google Scholar
|
|
5
|
Meng X, Wu TG, Lou QY, Niu KY, Jiang L,
Xiao QZ, Xu T and Zhang L: Optimization of CRISPR-Cas system for
clinical cancer therapy. Bioeng Transl Med. 8:e104742022.
View Article : Google Scholar
|
|
6
|
Heler R, Marraffini LA and Bikard D:
Adapting to new threats: The generation of memory by CRISPR-Cas
immune systems. Mol Microbial. 93:1–9. 2014. View Article : Google Scholar
|
|
7
|
Faure G, Shmakov SA, Yan WX, Cheng DR,
Scott DA, Peters JE, Makarova KS and Koonin EV: CRISPR-Cas in
mobile genetic elements: Counter-defence and beyond. Nat Rev
Microbiol. 17:513–525. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hille F, Richter H, Wong SP, Bratovič M,
Ressel S and Charpentier E: The biology of CRISPR-Cas: Backward and
forward. Cell. 172:1239–1259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Der Oost J, Westra ER, Jackson RN and
Wiedenheft B: Unravelling the structural and mechanistic basis of
CRISPR-Cas systems. Nat Rev Microbiol. 12:479–492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Konermann S, Lotfy P, Brideau NJ, Oki J,
Shokhirev MN and Hsu PD: Transcriptome engineering with
RNA-targeting type VI-D CRISPR effectors. Cell. 173:665–676.e14.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan WX, Chong S, Zhang H, Makarova KS,
Koonin EV, Cheng DR and Scott DA: Cas13d is a compact RNA-targeting
type VI CRISPR effector positively modulated by a
WYL-domain-containing accessory protein. Mol Cell. 70:327–339.e5.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao F, Zhang T, Sun X, Zhang X, Chen L,
Wang H, Li J, Fan P, Lai L, Sui T and Li Z: A strategy for Cas13
miniaturization based on the structure and AlphaFold. Nat Commun.
14:55452023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Ye Y, Ye W, Perčulija V, Jiang H,
Chen Y, Li Y, Chen J, Lin J, Wang S, et al: Two HEPN domains
dictate CRISPR RNA maturation and target cleavage in Cas13d. Nat
Commun. 10:25442019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shan Y, Zhou X, Huang R and Xing D:
High-fidelity and rapid quantification of miRNA combining crRNA
programmability and CRISPR/Cas13a trans-cleavage activity. Anal
Chem. 91:5278–5285. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang H and Patel DJ: Structures,
mechanisms and applications of RNA-centric CRISPR-Cas13. Nat Chem
Biol. 20:673–688. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan
T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in
targeted cancer therapy: Advances, challenges, and future
perspectives. Signal Transduct Target Ther. 6:2012021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Allemailem KS, Almatroodi SA, Almatroudi
A, Alrumaihi F, Al Abdulmonem W, Al-Megrin WAI, Aljamaan AN,
Rahmani AH and Khan AA: Recent advances in genome-editing
technology with CRISPR/Cas9 variants and stimuli-responsive
targeting approaches within tumor cells: A future perspective of
cancer management. Int J Mol Sci. 24:70522023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pulumati A, Pulumati A, Dwarakanath BS,
Verma A and Papineni RVL: Technological advancements in cancer
diagnostics: Improvements and limitations. Cancer Rep (Hoboken).
6:e17642023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang L, Dai C, Jiang L, Tong G, Xiong Y,
Khan K, Tang Z, Chen X and Zeng H: Advanced devices for tumor
diagnosis and therapy. Small. 17:e21000032021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Allemailem KS, Alsahli MA, Almatroudi A,
Alrumaihi F, Al Abdulmonem W, Moawad AA, Alwanian WM, Almansour NM,
Rahmani AH and Khan AA: Innovative strategies of reprogramming
immune system cells by targeting CRISPR/Cas9-based genome-editing
tools: A new era of cancer management. Int J Nanomedicine.
18:5531–5559. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Allemailem KS, Almatroudi A, Alrumaihi F,
Alradhi AE, Theyab A, Algahtani M, Alhawas MO, Dobie G, Moawad AA,
Rahmani AH and Khan AA: Current updates of CRISPR/Cas system and
anti-CRISPR proteins: Innovative applications to improve the genome
editing strategies. Int J Nanomedicine. 19:10185–10212. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Palaz F, Kalkan AK, Can Ö, Demir AN,
Tozluyurt A, Özcan A and Ozsoz M: CRISPR-Cas13 system as a
promising and versatile tool for cancer diagnosis, therapy, and
research. ACS Synth Biol. 10:1245–1267. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Durán-Vinet B, Araya-Castro K, Calderón J,
Vergara L, Weber H, Retamales J, Araya-Castro P and Leal-Rojas P:
CRISPR/ Cas13-based platforms for a potential next-generation
diagnosis of colorectal cancer through exosomes micro-RNA
detection: A review. Cancers (Basel). 13:46402021. View Article : Google Scholar
|
|
24
|
Xu D, Cai Y, Tang L, Han X, Gao F, Cao H,
Qi F and Kapranov P: A CRISPR/Cas13-based approach demonstrates
biological relevance of vlinc class of long non-coding RNAs in
anticancer drug response. Sci Rep. 10:17942020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abudayyeh OO, Gootenberg JS, Konermann S,
Joung J, Slaymaker IM, Cox DBT, Shmakov S, Makarova KS, Semenova E,
Minakhin L, et al: C2c2 is a single-component programmable
RNA-guided RNA-targeting CRISPR effector. Science. 353:aaf55732016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Núñez-Álvarez Y, Espie-Caullet T, Buhagiar
G, Rubio-Zulaika A, Alonso-Marañón J, Luna-Pérez E, Blazquez L and
Luco RF: A CRISPR-dCas13 RNA-editing tool to study alternative
splicing. Nucleic Acids Res. 52:11926–11939. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Apostolopoulos A, Kawamoto N, Chow SYA,
Tsuiji H, Ikeuchi Y, Shichino Y and Iwasaki S: dCas13-mediated
translational repression for accurate gene silencing in mammalian
cells. Nat Commun. 15:22052024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deltcheva E, Chylinski K, Sharma CM,
Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J and Charpentier
E: CRISPR RNA maturation by trans-encoded small RNA and host factor
RNase III. Nature. 471:602–607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barrangou R, Fremaux C, Deveau H, Richards
M, Boyaval P, Moineau S, Romero DA and Horvath P: CRISPR provides
acquired resistance against viruses in prokaryotes. Science.
315:1709–1712. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rananaware SR, Vesco EK, Shoemaker GM,
Anekar SS, Sandoval LSW, Meister KS, Macaluso NC, Nguyen LT and
Jain PK: Programmable RNA detection with CRISPR-Cas12a. Nat Commun.
14:54092023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Allemailem KS: Recent advances in
understanding the molecular mechanisms of multidrug resistance and
novel approaches of CRISPR/Cas9-based genome-editing to combat this
health emergency. Int J Nanomedicine. 19:1125–1143. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McGinn J and Marraffini LA: Molecular
mechanisms of CRISPR-Cas spacer acquisition. Nat Rev Microbiol.
17:7–12. 2019. View Article : Google Scholar
|
|
33
|
Makarova KS, Wolf YI and Koonin EV:
Evolutionary classification of CRISPR-Cas systems. Crispr: Biology
and Applications. 13–38. 2022. View Article : Google Scholar
|
|
34
|
Koonin EV, Makarova KS and Zhang F:
Diversity, classification and evolution of CRISPR-Cas systems. Curr
Opin Microbiol. 37:67–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan F, Wang W and Zhang J: CRISPR-Cas12
and Cas13: The lesser known siblings of CRISPR-Cas9. Cell Biol
Toxicol. 35:489–492. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Makarova KS, Haft DH, Barrangou R, Brouns
SJ, Charpentier E, Horvath P, Moineau S, Mojica FJ, Wolf YI,
Yakunin AF, et al: Evolution and classification of the CRISPR-Cas
systems. Nat Rev Microbiol. 9:467–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Steens JA, Bravo JPK, Salazar CR, Yildiz
C, Amieiro AM, Köstlbacher S, Prinsen SHP, Andres AS, Patinios C,
Bardis A, et al: Type III-B CRISPR-Cas cascade of proteolytic
cleavages. Science. 383:512–519. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shabalina SA and Koonin EV: Origins and
evolution of eukaryotic RNA interference. Trends Ecol Evol.
23:578–587. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Makarova KS, Wolf YI, Iranzo J, Shmakov
SA, Alkhnbashi OS, Brouns SJJ, Charpentier E, Cheng D, Haft DH,
Horvath P, et al: Evolutionary classification of CRISPR-Cas
systems: A burst of class 2 and derived variants. Nat Rev
Microbiol. 18:67–83. 2020. View Article : Google Scholar
|
|
40
|
Brouns SJ, Jore MM, Lundgren M, Westra ER,
Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV and
Van Der Oost J: Small CRISPR RNAs guide antiviral defense in
prokaryotes. Science. 321:960–964. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen XD, Chen Z, Wythes G, Zhang Y, Orr
BC, Sun G, Chao YK, Navarro Torres A, Thao K, Vallurupalli M, et
al: Helicase-assisted continuous editing for programmable
mutagenesis of endogenous genomes. Science. 386:eadn58762024.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jinek M, Chylinski K, Fonfara I, Hauer M,
Doudna JA and Charpentier E: A programmable dual-RNA-guided DNA
endonuclease in adaptive bacterial immunity. Science. 337:816–821.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chylinski K, Makarova KS, Charpentier E
and Koonin EV: Classification and evolution of type II CRISPR-Cas
systems. Nucleic Acids Res. 42:6091–6105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Marraffini LA and Sontheimer EJ: CRISPR
interference limits horizontal gene transfer in staphylococci by
targeting DNA. Science. 322:1843–1845. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stella G and Marraffini L: Type III
CRISPR-Cas: Beyond the Cas10 effector complex. Trends Biochem Sci.
49:28–37. 2024. View Article : Google Scholar :
|
|
46
|
Zhou Y, Bravo JPK, Taylor HN, Steens JA,
Jackson RN, Staals RHJ and Taylor DW: Structure of a type IV
CRISPR-Cas ribonucleoprotein complex. iScience. 24:1022012021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zetsche B, Gootenberg JS, Abudayyeh OO,
Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, Van
Der Oost J, Regev A, et al: Cpf1 is a single RNA-guided
endonuclease of a class 2 CRISPR-Cas system. Cell. 163:759–771.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao P, Yang H, Rajashankar KR, Huang Z and
Patel DJ: Type V CRISPR-Cas Cpf1 endonuclease employs a unique
mechanism for crRNA-mediated target DNA recognition. Cell Res.
26:901–913. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Abudayyeh OO, Gootenberg JS,
Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, Cox DB,
Kellner MJ, Regev A, et al: RNA targeting with CRISPR-Cas13.
Nature. 550:280–284. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
van Beljouw SPB, Sanders J,
Rodríguez-Molina A and Brouns SJJ: RNA-targeting CRISPR-Cas
systems. Nat Rev Microbiol. 21:21–34. 2023. View Article : Google Scholar
|
|
51
|
Liu L, Li X, Ma J, Li Z, You L, Wang J,
Wang M, Zhang X and Wang Y: The molecular architecture for
RNA-guided RNA cleavage by Cas13a. Cell. 170:714–726.e10. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu C, Zhou Y, Xiao Q, He B, Geng G, Wang
Z, Cao B, Dong X, Bai W, Wang Y, et al: Programmable RNA editing
with compact CRISPR-Cas13 systems from uncultivated microbes. Nat
Methods. 18:499–506. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Perčulija V, Lin J, Zhang B and Ouyang S:
Functional features and current applications of the RNA-targeting
type VI CRISPR-Cas systems. Adv Sci (Weinh). 8:20046852021.
View Article : Google Scholar
|
|
54
|
Hu Y, Chen Y, Xu J, Wang X, Luo S, Mao B,
Zhou Q and Li W: Metagenomic discovery of novel CRISPR-Cas13
systems. Cell Discov. 8:1072022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
O'Connell MR: Molecular mechanisms of RNA
targeting by Cas13-containing type VI CRISPR-Cas systems. J Mol
Biol. 431:66–87. 2019. View Article : Google Scholar
|
|
56
|
Gootenberg JS, Abudayyeh OO, Lee JW,
Essletzbichler P, Dy AJ, Joung J, Verdine V, Donghia N, Daringer
NM, Freije CA, et al: Nucleic acid detection with
CRISPR-Cas13a/C2c2. Science. 356:438–442. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tambe A, East-Seletsky A, Knott GJ, Doudna
JA and O'Connell MR: RNA binding and HEPN-nuclease activation are
decoupled in CRISPR-Cas13a. Cell Rep. 24:1025–1036. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Meeske AJ, Nakandakari-Higa S and
Marraffini LA: Cas13-induced cellular dormancy prevents the rise of
CRISPR-resistant bacteriophage. Nature. 570:241–245. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tong H, Huang J, Xiao Q, He B, Dong X, Liu
Y, Yang X, Han D, Wang Z, Wang X, et al: High-fidelity Cas13
variants for targeted RNA degradation with minimal collateral
effects. Nat Biotechnol. 41:108–119. 2023. View Article : Google Scholar
|
|
60
|
VanderWal AR, Park JU, Polevoda B, Kellogg
EH and O'Connell MR: CRISPR-Csx28 forms a Cas13b-activated membrane
pore required for robust CRISPR-Cas adaptive immunity. Science.
380:66432023.
|
|
61
|
Guan J, Oromí-Bosch A, Mendoza SD,
Karambelkar S, Berry J and Bondy-Denomy J: RNA targeting with
CRISPR-Cas13a facilitates bacteriophage genome engineering.
BioRxiv. View Article : Google Scholar
|
|
62
|
Shmakov S, Abudayyeh OO, Makarova KS, Wolf
YI, Gootenberg JS, Semenova E, Minakhin L, Joung J, Konermann S,
Severinov K, et al: Discovery and functional characterization of
diverse class 2 CRISPR-Cas systems. Mol Cell. 60:385–397. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Deng X, Osikpa E, Yang J, Oladeji SJ,
Smith J, Gao X and Gao Y: Structural basis for the activation of a
compact CRISPR-Cas13 nuclease. Nat Commun. 14:58452023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
East-Seletsky A, O'Connell MR, Burstein D,
Knott GJ and Doudna JA: RNA targeting by functionally orthogonal
type VI-A CRISPR-Cas enzymes. Mol Cell. 66:373–383.e3. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Knott GJ, East-Seletsky A, Cofsky JC,
Holton JM, Charles E, O'Connell MR and Doudna JA: Guide-bound
structures of an RNA-targeting A-cleaving CRISPR-Cas13a enzyme. Nat
Struct Mol Biol. 24:825–833. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liu L, Li X, Wang J, Wang M, Chen P, Yin
M, Li J, Sheng G and Wang Y: Two distant catalytic sites are
responsible for C2c2 RNase activities. Cell. 168:121–134.e12. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Charles EJ, Kim SE, Knott GJ, Smock D,
Doudna J and Savage DF: Engineering improved Cas13 effectors for
targeted post-transcriptional regulation of gene expression.
BioRxiv. View Article : Google Scholar
|
|
68
|
Molina Vargas AM, Sinha S, Osborn R,
Arantes PR, Patel A, Dewhurst S, Hardy DJ, Cameron A, Palermo G and
O'Connell MR: New design strategies for ultra-specific
CRISPR-Cas13a-based RNA detection with single-nucleotide mismatch
sensitivity. Nucleic Acids Res. 52:921–939. 2024. View Article : Google Scholar :
|
|
69
|
East-Seletsky A, O'Connell MR, Knight SC,
Burstein D, Cate JHD, Tjian R and Doudna JA: Two distinct RNase
activities of CRISPR-C2c2 enable guide-RNA processing and RNA
detection. Nature. 538:270–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ai Y, Liang D and Wilusz JE: CRISPR/Cas13
effectors have differing extents of off-target effects that limit
their utility in eukaryotic cells. Nucleic Acids Res. 50:e652022.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang T, Zhao Y, Ye J, Cao X, Xu C, Chen
B, An H, Jiao Y, Zhang F, Yang X and Zhou G: Establishing
CRISPR/Cas13a immune system conferring RNA virus resistance in both
dicot and monocot plants. Plant Biotechnol J. 17:1185–1187. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kick LM, Von Wrisberg MK, Runtsch LS and
Schneider S: Structure and mechanism of the RNA dependent RNase
Cas13a from Rhodobacter capsulatus. Commun Biol. 5:712022.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Smargon AA, Cox DBT, Pyzocha NK, Zheng K,
Slaymaker IM, Gootenberg JS, Abudayyeh OA, Essletzbichler P,
Shmakov S, Makarova KS, et al: Cas13b is a type VI-B
CRISPR-associated RNA-guided RNase differentially regulated by
accessory proteins Csx27 and Csx28. Mol Cell. 65:618–630.e7. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
VanderWal AR, Park JU, Polevoda B, Nicosia
JK, Molina Vargas AM, Kellogg EH and O'Connell MR: Csx28 is a
membrane pore that enhances CRISPR-Cas13b-dependent antiphage
defense. Science. 380:410–415. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang B, Ye W, Ye Y, Zhou H, Saeed AFUH,
Chen J, Lin J, Perčulija V, Chen Q, Chen CJ, et al: Structural
insights into Cas13b-guided CRISPR RNA maturation and recognition.
Cell Res. 28:1198–1201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Slaymaker IM, Mesa P, Kellner MJ, Kannan
S, Brignole E, Koob J, Feliciano PR, Stella S, Abudayyeh OO,
Gootenberg JS, et al: High-resolution structure of Cas13b and
biochemical characterization of RNA targeting and cleavage. Cell
Rep. 26:3741–3751.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bhoobalan-Chitty Y, Stouf M and De Paepe
M: Genetic manipulation of Bacteriophage T4 utilizing the
CRISPR-Cas13b system. bioRxiv. View Article : Google Scholar
|
|
78
|
Liu L and Pei DS: Insights gained from RNA
editing targeted by the CRISPR-Cas13 family. Int J Mol Sci.
23:114002022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kavuri NR, Ramasamy M, Qi Y and Mandadi K:
Applications of CRISPR/Cas13-based RNA editing in plants. Cells.
11:26652022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Umaña A and Slade DJ: CRISPR-Cas systems
in Fusobacterium: An untapped genetic frontier. bioRxiv. View Article : Google Scholar
|
|
81
|
Hussein M, Liu Y, Vink M, Kroon PZ, Das
AT, Berkhout B and Herrera-Carrillo E: Evaluation of the effect of
RNA secondary structure on Cas13d-mediated target RNA cleavage. Mol
Ther Nucleic Acids. 35:1022782024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wessels HH, Stirn A, Méndez-Mancilla A,
Kim EJ, Hart SK, Knowles DA and Sanjana NE: Prediction of on-target
and off-target activity of CRISPR-Cas13d guide RNAs using deep
learning. Nat Biotechnol. 42:628–637. 2024. View Article : Google Scholar
|
|
83
|
Gupta R, Ghosh A, Chakravarti R, Singh R,
Ravichandiran V, Swarnakar S and Ghosh D: Cas13d: A new molecular
scissor for transcriptome engineering. Front Cell Dev Biol.
10:8668002022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Tang XZ, Tan SX, Hoon S and Yeo GW:
Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in
humans. Nat Med. 28:1372–1376. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Kordyś M, Sen R and Warkocki Z:
Applications of the versatile CRISPR-Cas13 RNA targeting system.
Wiley Interdiscip Rev RNA. 13:e16942022. View Article : Google Scholar
|
|
86
|
Liu Y, Jing P, Zhou Y, Zhang J, Shi J,
Zhang M, Yang H and Fei J: The effects of length and sequence of
gRNA on Cas13b and Cas13d activity in vitro and in vivo. Biotechnol
J. 18:e23000022023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang C, Konermann S, Brideau NJ, Lotfy P,
Wu X, Novick SJ, Strutzenberg T, Griffin PR, Hsu PD and Lyumkis D:
Structural basis for the RNA-guided ribonuclease activity of
CRISPR-Cas13d. Cell. 175:212–223.e17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhang K, Zhang Z, Kang J, Chen J, Liu J,
Gao N, Fan L, Zheng P, Wang Y and Sun J: CRISPR/Cas13d-mediated
microbial RNA knockdown. Front Bioeng Biotechnol. 8:8562020.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Nakagawa R, Kannan S, Altae-Tran H, Takeda
SN, Tomita A, Hirano H, Kusakizako T, Nishizawa T, Yamashita K,
Zhang F, et al: Structure and engineering of the minimal type VI
CRISPR-Cas13bt3. Mol Cell. 82:3178–3192.e5. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Mahas A, Wang Q, Marsic T and Mahfouz MM:
A novel miniature CRISPR-Cas13 system for SARS-CoV-2 diagnostics.
ACS Synth Biol. 10:2541–2551. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Mehta A and Merkel OM: Immunogenicity of
Cas9 protein. J Pharm Sci. 109:62–67. 2020. View Article : Google Scholar :
|
|
92
|
Kushawah G, Hernandez-Huertas L,
Abugattas-Nuñez Del Prado J, Martinez-Morales JR, DeVore ML, Hassan
H, Moreno-Sanchez I, Tomas-Gallardo L, Diaz-Moscoso A, Monges DE,
et al: CRISPR-Cas13d induces efficient mRNA knockdown in animal
embryos. Dev Cell. 54:805–817.e7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhou C, Hu X, Tang C, Liu W, Wang S, Zhou
Y, Zhao Q, Bo Q, Shi L, Sun X, et al: CasRx-mediated RNA targeting
prevents choroidal neovascularization in a mouse model of
age-related macular degeneration. Natl Sci Rev. 7:835–837. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhou H, Su J, Hu X, Zhou C, Li H, Chen Z,
Xiao Q, Wang BO, Wu W, Sun Y, et al: Glia-to-neuron conversion by
CRISPR-CasRx alleviates symptoms of neurological disease in mice.
Cell. 181:590–603.e16. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Granados-Riveron JT and Aquino-Jarquin G:
CRISPR-Cas13 precision transcriptome engineering in cancer. Cancer
Res. 78:4107–4113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Yazdi ZF, Roshannezhad S, Sharif S and
Abbaszadegan MR: Recent progress in prompt molecular detection of
liquid biopsy using Cas enzymes: Innovative approaches for cancer
diagnosis and analysis. J Transl Med. 22:11732024. View Article : Google Scholar
|
|
97
|
Kellner MJ, Koob JG, Gootenberg JS,
Abudayyeh OO and Zhang F: SHERLOCK: Nucleic acid detection with
CRISPR nucleases. Nat Protoc. 14:2986–3012. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Patchsung M, Jantarug K, Pattama A,
Aphicho K, Suraritdechachai S, Meesawat P, Sappakhaw K, Leelahakorn
N, Ruenkam T, Wongsatit T, et al: Clinical validation of a
Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat Biomed
Eng. 4:1140–1149. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gao J, Luo T, Lin N, Zhang S and Wang J: A
new tool for CRISPR-Cas13a-based cancer gene therapy. Mol Ther
Oncolytics. 19:79–92. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Usuba W, Urabe F, Yamamoto Y, Matsuzaki J,
Sasaki H, Ichikawa M, Takizawa S, Aoki Y, Niida S, Kato K, et al:
Circulating miRNA panels for specific and early detection in
bladder cancer. Cancer Sci. 110:408–419. 2019. View Article : Google Scholar :
|
|
101
|
Liu R, Chen X, Du Y, Yao W, Shen L, Wang
C, Hu Z, Zhuang R, Ning G, Zhang C, et al: Serum microRNA
expression profile as a biomarker in the diagnosis and prognosis of
pancreatic cancer. Clin Chem. 58:610–618. 2012. View Article : Google Scholar
|
|
102
|
Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao
X, Zhu W, Zhang X, Cheng Y, Ou K, et al: Circulating lncRNAs
associated with occurrence of colorectal cancer progression. Am J
Cancer Res. 5:2258–2265. 2015.PubMed/NCBI
|
|
103
|
Sheng Y, Zhang T, Zhang S, Johnston M,
Zheng X, Shan Y, Liu T, Huang Z, Qian F, Xie Z, et al: A
CRISPR/Cas13a-powered catalytic electrochemical biosensor for
successive and highly sensitive RNA diagnostics. Biosens
Bioelectron. 178:1130272021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cescon DW, Bratman SV, Chan SM and Siu LL:
Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer.
1:276–290. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Rothwell DG, Ayub M, Cook N,
Thistlethwaite F, Carter L, Dean E, Smith N, Villa S, Dransfield J,
Clipson A, et al: Utility of ctDNA to support patient selection for
early phase clinical trials: The TARGET study. Nat Med. 25:738–743.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhang X, Tian Y, Xu L, Fan Z, Cao Y, Ma Y,
Li H and Ren F: CRISPR/Cas13-assisted hepatitis B virus covalently
closed circular DNA detection. Hepatol Int. 16:306–315. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Antropov DN and Stepanov GA: Molecular
mechanisms underlying CRISPR/Cas-based assays for nucleic acid
detection. Curr Issues Mol Biol. 45:649–662. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Gootenberg JS, Abudayyeh OO, Kellner MJ,
Joung J, Collins JJ and Zhang F: Multiplexed and portable nucleic
acid detection platform with Cas13, Cas12a, and Csm6. Science.
360:439–444. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Myhrvold C, Freije CA, Gootenberg JS,
Abudayyeh OO, Metsky HC, Durbin AF, Kellner MJ, Tan AL, Paul LM,
Parham LA, et al: Field-deployable viral diagnostics using
CRISPR-Cas13. Science. 360:444–448. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Bianchi F, Nicassio F, Marzi M, Belloni E,
Dall'Olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G and Di
Fiore PP: A serum circulating miRNA diagnostic test to identify
asymptomatic high-risk individuals with early stage lung cancer.
EMBO Mol Med. 3:495–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Zhang L, Xu Y, Jin X, Wang Z, Wu Y, Zhao
D, Chen G, Li D, Wang X, Cao H, et al: A circulating miRNA
signature as a diagnostic biomarker for non-invasive early
detection of breast cancer. Breast Cancer Res Treat. 154:423–434.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhou T, Huang R, Huang M, Shen J, Shan Y
and Xing D: CRISPR/Cas13a powered portable electrochemiluminescence
chip for ultrasensitive and specific MiRNA detection. Adv Sci
(Weinh). 7:19036612020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Bruch R, Baaske J, Chatelle C, Meirich M,
Madlener S, Weber W, Dincer C and Urban GA: CRISPR/Cas13a-powered
electrochemical microfluidic biosensor for nucleic acid
amplification-free miRNA diagnostics. Adv Mater. 31:e19053112019.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Bruch R, Johnston M, Kling A, Mattmüller
T, Baaske J, Partel S, Madlener S, Weber W, Urban GA and Dincer C:
CRISPR-powered electrochemical microfluidic multiplexed biosensor
for target amplification-free miRNA diagnostics. Biosens
Bioelectron. 177:1128872021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Ruivo CF, Adem B, Silva M and Melo SA: The
biology of cancer exosomes: Insights and new perspectives. Cancer
Res. 77:6480–6488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Contreras-Naranjo JC, Wu HJ and Ugaz VM:
Microfluidics for exosome isolation and analysis: Enabling liquid
biopsy for personalized medicine. Lab Chip. 17:3558–3577. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Li W, Li C, Zhou T, Liu X, Liu X, Li X and
Chen D: Role of exosomal proteins in cancer diagnosis. Mol Cancer.
16:1452017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Li A, Zhang T, Zheng M, Liu Y and Chen Z:
Exosomal proteins as potential markers of tumor diagnosis. J
Hematol Oncol. 10:1752017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Shao H, Im H, Castro CM, Breakefield X,
Weissleder R and Lee H: New technologies for analysis of
extracellular vesicles. Chem Rev. 118:1917–1950. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
He Y, Wu Y, Wang Y, Wang X, Xing S, Li H,
Guo S, Yu X, Dai S, Zhang G, et al: Applying CRISPR/Cas13 to
construct exosomal PD-L1 ultrasensitive biosensors for dynamic
monitoring of tumor progression in immunotherapy. Adv Therap.
3:20000932020. View Article : Google Scholar
|
|
121
|
Chen Q, Tian T, Xiong E, Wang P and Zhou
X: CRISPR/Cas13a signal amplification linked immunosorbent assay
for femtomolar protein detection. Anal Chem. 92:573–577. 2020.
View Article : Google Scholar
|
|
122
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Chen Y, Jiang H, Wang T, He D, Tian R, Cui
Z, Tian X, Gao Q, Ma X, Yang J, et al: In vitro and in vivo growth
inhibition of human cervical cancer cells via human papillomavirus
E6/ E7 mRNAs' cleavage by CRISPR/Cas13a system. Antiviral Res.
178:1047942020. View Article : Google Scholar
|
|
124
|
Zhang Z, Wang Q, Liu Q, Zheng Y, Zheng C,
Yi K, Zhao Y, Gu Y, Wang Y, Wang C, et al: Dual-locking
nanoparticles disrupt the PD-1/PD-L1 pathway for efficient cancer
immunotherapy. Adv Mater. 31:e19057512019. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Jiang W, Li H, Liu X, Zhang J, Li T, Liu L
and Yu X: Precise and efficient silencing of mutant
KrasG12D by CRISPR-CasRx controls pancreatic cancer
progression. Theranostics. 10:115072020. View Article : Google Scholar :
|
|
126
|
Yue H, Huang R, Shan Y and Xing D:
Delivery of Cas13a/ crRNA by self-degradable black phosphorus
nanosheets to specifically inhibit Mcl-1 for breast cancer therapy.
J Mater Chem B. 8:11096–11106. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lin P, Qin S, Pu Q, Wang Z, Wu Q, Gao P,
Schettler J, Guo K, Li R, Li G, et al: CRISPR-Cas13 inhibitors
block RNA editing in bacteria and mammalian cells. Mol Cell.
78:850–861. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Meeske AJ, Jia N, Cassel AK, Kozlova A,
Liao J, Wiedmann M, Patel DJ and Marraffini LA: A phage-encoded
anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas
immunity. Science. 369:54–59. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Bubeck F, Hoffmann MD, Harteveld Z,
Aschenbrenner S, Bietz A, Waldhauer MC, Börner K, Fakhiri J,
Schmelas C, Dietz L, et al: Engineered anti-CRISPR proteins for
optogenetic control of CRISPR-Cas9. Nat Methods. 15:924–927. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lee J, Mou H, Ibraheim R, Liang SQ, Liu P,
Xue W and Sontheimer EJ: Tissue-restricted genome editing in vivo
specified by microRNA-repressible anti-CRISPR proteins. RNA.
25:1421–1431. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Fan J, Liu Y, Liu L, Huang Y, Li X and
Huang W: A multifunction lipid-based CRISPR-Cas13a genetic circuit
delivery system for bladder cancer gene therapy. ACS Synth Biol.
9:343–355. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kopparapu PK, Boorjian SA, Robinson BD,
Downes M, Gudas LJ, Mongan NP and Persson JL: Expression of VEGF
and its receptors VEGFR1/VEGFR2 is associated with invasiveness of
bladder cancer. Anticancer Res. 33:2381–2390. 2013.PubMed/NCBI
|
|
133
|
Liu L, Liu Y, Zhang T, Wu H, Lin M, Wang
C, Zhan Y, Zhou Q, Qiao B, Sun X, et al: Synthetic Bax-Anti Bcl2
combination module actuated by super artificial hTERT promoter
selectively inhibits malignant phenotypes of bladder cancer. J Exp
Clin Cancer Res. 35:32016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang D, Tang H, Xu X, Dai W, Wu J and Wang
J: Control the intracellular NF-κB activity by a sensor consisting
of miRNA and decoy. Int J Biochem Cell Biol. 95:43–52. 2018.
View Article : Google Scholar
|
|
135
|
Dai W, Wu J, Wang D and Wang J: Cancer
gene therapy by NF-κB-activated cancer cell-specific expression of
CRISPR/ Cas9 targeting telomeres. Gene Ther. 27:266–280. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wang D, Dai W and Wang J: A cell-specific
nuclear factor-kappa B-activating gene expression strategy for
delivering cancer immunotherapy. Hum Gene Ther. 30:471–484. 2019.
View Article : Google Scholar
|
|
137
|
Rahib L, Wehner MR, Matrisian LM and Nead
KT: Estimated projection of US cancer incidence and death to 2040.
JAMA Netw Open. 4:e2147082021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Halbrook CJ, Lyssiotis CA, di Magliano MP
and Maitra A: Pancreatic cancer: Advances and challenges. Cell.
186:1729–1754. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Linehan A, O'Reilly M, McDermott R and
O'Kane GM: Targeting KRAS mutations in pancreatic cancer:
Opportunities for future strategies. Front Med (Lausanne).
11:13691362024. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Amintas S, Cullot G, Boubaddi M, Rébillard
J, Karembe L, Turcq B, Prouzet-Mauléon V, Bedel A, Moreau-Gaudry F,
Cappellen D and Dabernat S: Integrating allele-specific PCR with
CRISPR-Cas13a for sensitive KRAS mutation detection in pancreatic
cancer. J Biol Eng. 18:532024. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Zhao X, Liu L, Lang J, Cheng K, Wang Y, Li
X, Shi J, Wang Y and Nie G: A CRISPR-Cas13a system for efficient
and specific therapeutic targeting of mutant KRAS for pancreatic
cancer treatment. Cancer Lett. 431:171–181. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Zhang Y, Li S, Li R, Qiu X, Fan T, Wang B,
Zhang B and Zhang L: Advances in application of CRISPR-Cas13a
system. Front Cell Infect Microbiol. 14:12915572024. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Kluth LA, Black PC, Bochner BH, Catto J,
Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E and Shariat
SF: Prognostic and prediction tools in bladder cancer: A
comprehensive review of the literature. Eur Urol. 68:238–253. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Wéber A, Vignat J, Shah R, Morgan E,
Laversanne M, Nagy P, Kenessey I and Znaor A: Global burden of
bladder cancer mortality in 2020 and 2040 according to GLOBOCAN
estimates. World J Urol. 42:2372024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Liang M, Wang Y, Liu L, Deng D, Yan Z,
Feng L, Kong C, Li C, Li Y and Li G: Synergistic intravesical
instillation for bladder cancer: CRISPR-Cas13a and fenbendazole
combination therapy. J Exp Clin Cancer Res. 43:2232024. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Zhou L, Li Y, Wang H, Qin R, Han Z and Li
R: Global cervical cancer elimination: Quantifying the status,
progress, and gaps. BMC Med. 23:672025. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Matsukura T and Sugase M: Pitfalls in the
epidemiologic classification of human papillomavirus types
associated with cervical cancer using polymerase chain reaction:
Driver and passenger. Int J Gynecol Cancer. 18:1042–1050. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Goodwin EC and DiMaio D: Repression of
human papillomavirus oncogenes in HeLa cervical carcinoma cells
causes the orderly reactivation of dormant tumor suppressor
pathways. Proc Natl Acad Sci USA. 97:12513–12518. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Pellerino A, Caccese M, Padovan M,
Cerretti G and Lombardi G: Epidemiology, risk factors, and
prognostic factors of gliomas. Clin Transl Imaging. 10:467–475.
2022. View Article : Google Scholar
|
|
150
|
Verhaak RGW, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Wang Q, Liu X, Zhou J, Yang C, Wang G, Tan
Y, Wu Y, Zhang S, Yi K and Kang C: The CRISPR-Cas13a gene-editing
system induces collateral cleavage of RNA in glioma cells. Adv Sci
(Weinh). 6:19012992019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Di Carlo E and Sorrentino C: State of the
art CRISPR-based strategies for cancer diagnostics and treatment.
Biomark Res. 12:1562024. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Azeez SS, Hamad RS, Hamad BK, Shekha MS
and Bergsten P: Advances in CRISPR-Cas technology and its
applications: Revolutionising precision medicine. Front Genome Ed.
6:15099242024. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chehelgerdi M, Chehelgerdi M,
Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F,
Rashidi M, Arshi A and Mokhtari-Farsani A: Comprehensive review of
CRISPR-based gene editing: mechanisms, challenges, and applications
in cancer therapy. Mol Cancer. 23:92024. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Mousavi Kahaki SA, Ebrahimzadeh N, Fahimi
H and Moshiri A: Development of an optimized protocol for
generating knockout cancer cell lines using the CRISPR/Cas9 system,
with emphasis on transient transfection. PLoS One. 19:e03103682024.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Tian T, Shu B, Jiang Y, Ye M, Liu L, Guo
Z, Han Z, Wang Z and Zhou X: An ultralocalized Cas13a assay enables
universal and nucleic acid amplification-free single-molecule RNA
diagnostics. ACS Nano. 15:1167–1178. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Zhou T, Huang M, Lin J, Huang R and Xing
D: High-fidelity CRISPR/Cas13a trans-cleavage-triggered rolling
circle amplified DNAzyme for visual profiling of microRNA. Anal
Chem. 93:2038–2044. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Sha Y, Huang R, Huang M, Yue H, Shan Y, Hu
J and Xing D: Cascade CRISPR/cas enables amplification-free
microRNA sensing with fM-sensitivity and single-base-specificity.
Chem Commun (Camb). 57:247–250. 2021. View Article : Google Scholar
|
|
159
|
Cui Y, Fan S, Yuan Z, Song M, Hu J, Qian
D, Zhen D, Li J and Zhu B: Ultrasensitive electrochemical assay for
microRNA-21 based on CRISPR/Cas13a-assisted catalytic hairpin
assembly. Talanta. 224:1218782021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Huang M, Huang R, Yue H, Shan Y and Xing
D: Ultrasensitive and high-specific microRNA detection using
hyper-branching rolling circle amplified CRISPR/Cas13a biosensor.
Sens Actuat B Chem. 325:1287992020. View Article : Google Scholar
|
